A 61-year-old female with KRAS wild- type metastatic colon cancer was initially treated with FOLFOX. After 6 months of chemotherapy, she experienced a partial response to treatment and therapy was...

Extracted text: A 61-year-old female with KRAS wild- type metastatic colon cancer was initially treated with FOLFOX. After 6 months of chemotherapy, she experienced a partial response to treatment and therapy was continued. Four months later, she developed worsening abdominal pain and an abdominal CT scan showed new sites of disease in her liver. Her oncologist changed her treatment regimen to FOLFIRI plus bevacizumab. Two months later, imaging studies show an increase in the size and number of liver metastases. Which of the following modifications to her current treatment regimen is now most appropriate? Select one: a. Discontinue current regimen; start irinotecan plus cetuximab b. Discontinue current regimen; start FOLFOXIRI plus panitumumab c. Continue FOLFIRI and bevacizumab; add cetuximab